ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Real-World Performance and Mid-Term Durability of the Myval Transcatheter Heart Valve in Patients Undergoing Transcatheter Aortic Valve Replacement.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Myval Transcatheter Heart Valve (THV) was designed to address limitations of earlier devices, such as paravalvular leak and sizing restrictions. The LANDMARK trial showed non-inferior short-term outcomes versus established valves in a randomized population of patients with severe aortic stenosis eligible for TAVR with the compared devices. However, confirmation of these findings in routine clinical practice remains important. This study evaluates the real-world safety, efficacy, and mid-term durability of Myval in severe aortic stenosis.
aimsThis study evaluates the real-world safety, efficacy, and mid-term durability of the Myval THV in patients with severe symptomatic aortic stenosis undergoing TAVR in a consecutive single-center registry.
methodsWe conducted a retrospective, single-center, single-arm study including 214 consecutive patients who underwent Myval THV implantation between December 2020 and February 2025, with at least 30-day follow-up. Clinical events were reported as incidence rates per 100 patient-years, and hemodynamic performance was assessed using mean profile charts with 95% confidence intervals.
resultsAmong 214 patients (mean age 77 years; 41% female), procedural success was 97.7%. Aortic valve area increased from 0.68 cm
conclusionIn this real-world cohort, TAVR with the Myval THV showed high procedural success, sustained mid-term hemodynamic improvement, and complication rates comparable to benchmark devices. These findings support its potential as a safe and effective option for severe aortic stenosis, although confirmation in larger, multicentre studies with extended follow-up is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.